SEC Form 4 · accession 0001104659-18-073869
Adaptimmune Therapeutics PLC · ADAP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lawrence M Alleva
Director
Period of report
Dec 17, 2018
Accepted (ET)
Dec 19, 2018 · 8:04 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001621227
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares with a nominal value of GBP0.001 per shareF1,F2,F3 | Dec 17, 2018 | P | 47,280 | $0.84 | A | 47,280 | I | Held by Trust |
| Ordinary Shares with a nominal value of GBP0.001 per shareF4 | holding | — | — | — | 70,584 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADS") and are held in the form of ADSs by the Lawrence M. Alleva Revocable Trust. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc.
- F2The 47,280 ordinary shares reported in Column 4 and Column 5 are represented by 7,880 ADSs.
- F3The price reported in Column 4 of $0.84 per ordinary share is derived from the purchase price paid on December 17, 2018 of $5.006 per ADS divided by six.
- F4The 70,584 ordinary shares reported in Column 5 are represented by 11,764 ADSs. These shares are held in the form of ADSs by Mr. Alleva.